EtoGesic

For Dog Pain Associated With Ostearthritis And Joint Conditions

EtoGesic Tablets by Fort Dodge are a nonsteroidal anti-inflammatory drug that can be given once daily to manage the pain and inflammation associated with osteoarthritis in dogs. With EtoGesic, dogs can move around more freely and enjoy a fuller, more active life. The product is rapidly absorbed, has a long half-life, and EtoGesic can be given once per day with or without food.

Etogesic (etodolac) For Dog Pain And Inflammation

Etogesic by Fort Dodge Is Recommended For The Management Of Pain And Inflammation Associated With Osteoarthritis In Dogs. EtoGesic Is Available As 150mg And 300mg Scored Tablets. It Should Not Be Used In Cats And Pregnant Or Nursing Animals.

What is this Etogesic used for:
Etodolac is a non-steroidal anti-inflammatory drug (NSAID) recommended for use in the management of pain and inflammation associated with osteoarthritis in dogs.

How EtoGesic should be used:
The recommended dose of etodolac in dogs is 10 to 15 mg/kg body weight (4.5 to 6.8 mg/lb) administered once daily. Due to tablet sizes and scoring, dogs weighing less than 5 kg (11 lb) cannot be accurately dosed. The effective dose and duration should be based on clinical judgment of disease condition and patient tolerance of drug treatment. The initial dose level should be adjusted until a satisfactory clinical response is obtained, but should not exceed 15 mg/kg once daily. When a satisfactory clinical response is obtained, the daily dose level should be reduced to the minimum effective dose for longer term administration.

Prescription Required

Etogesic 150Mg 30 Tablets Sale price: $19.99 Buy It!
Etogesic 150Mg 90 Tablets Sale price: $64.99 Buy It!

Etogesic 300Mg 30 Tablets Sale price: $39.99 Buy It!
Etogesic 300Mg 90 Tablets Sale price: $79.99 Buy It!

PRECAUTIONS
Treatment with EtoGesic tablets should be terminated if signs such as inappetence, emesis, fecal abnormalities, or anemia are observed. Dogs treated with nonsteroidal anti-inflammatory drugs, including etodolac, should be evaluated periodically to ensure that the drug is still necessary and well tolerated.

EtoGesic, as with other nonsteroidal anti-inflammatory drugs, may exacerbate clinical signs in dogs with pre-existing or occult gastrointestinal, hepatic or cardiovascular abnormalities, blood dyscrasias, or bleeding disorders.

As a class, cyclooxygenase inhibitory NSAIDs may be associated with gastrointestinal and renal toxicity. Sensitivity to drug-associated adverse effects varies with the individual patient. Patients at greatest risk for renal toxicity are those that are dehydrated, on concomitant diuretic therapy, or those with renal, cardiovascular, and/or hepatic dysfunction. Since many NSAIDs possess the potential to induce gastrointestinal ulceration, concomitant use of etodolac with other anti-inflammatory drugs, such as other NSAIDs and corticosteroids, should be avoided or closely monitored.

Studies to determine the activity of EtoGesic tablets when administered concomitantly with other protein-bound drugs have not been conducted in dogs. Drug compatibility should be monitored closely in patients requiring adjunctive therapy.

The safety of EtoGesic has not been investigated in breeding, pregnant or lactating dogs or in dogs under 12 months of age.